- Conditions
- Tumors, Central Nervous System
- Interventions
- Montanide
- Biological
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 791
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bevacizumab, quality-of-life assessment
- Biological · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois + 1 more
- Conditions
- Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma
- Interventions
- temozolomide and bevacizumab
- Drug
- Lead sponsor
- Center for Neurosciences, Tucson
- Other
- Eligibility
- 18 Years to 83 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Glioblastoma
- Interventions
- TransMID
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma, Recurrent Grade IV Glioma, Adult Anaplastic Oligodendroglioma, Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor, Adult Anaplastic Oligoastrocytoma, Recurrent High Grade Glioma
- Interventions
- flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-Tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, E. coli CD-expressing genetically modified neural stem cells
- Drug · Other · Biological + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS), Diffuse Intrinsic Pontine Gliomas (DIPG), Medulloblastoma
- Interventions
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Biological
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- sorafenib tosylate, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Sapanisertib, Telaglenastat Hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 2 more
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Medulloblastoma, Childhood Pineoblastoma, Childhood Soft Tissue Sarcoma, Childhood Supratentorial Primitive Neuroectodermal Tumor, Neuroblastoma, Osteosarcoma, Retinoblastoma, Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- filgrastim
- Biological
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carmustine, irinotecan hydrochloride
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma, WHO Grade III Glioma
- Interventions
- sorafenib tosylate, valproic acid, sildenafil citrate
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- becatecarin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 198
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Interventions
- palbociclib isethionate, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer, Pancreatic Cancer, Prostate Adenocarcinoma, Glioma, Primary Solid Tumors
- Interventions
- 131-I-TM-601 (chlorotoxin)
- Drug
- Lead sponsor
- TransMolecular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 2 more
- Conditions
- Recurrent Glioblastoma
- Interventions
- Activated T cells
- Biological
- Lead sponsor
- Jeremy Rudnick, M.D
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glioblastoma Multiforme
- Interventions
- TLN-4601
- Drug
- Lead sponsor
- Thallion Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- New York, New York • Durham, North Carolina
- Conditions
- Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
- Interventions
- GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide
- Biological · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma
- Interventions
- Nivolumab, NKTR-214
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- Up to 30 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas • St Louis, Missouri
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- O6-benzylguanine, temozolomide, conventional surgery
- Drug · Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Recurrent Glioblastoma Multiforme(GBM)
- Interventions
- ACT001, ACT001 + Pembrolizumab
- Drug
- Lead sponsor
- Accendatech USA Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma
- Interventions
- Capecitabine, Bevacizumab
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Central Nervous System Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer, Stage IV Breast Cancer, Tumors Metastatic to Brain
- Interventions
- methotrexate, liposomal cytarabine, quality-of-life assessment, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- 90Y-DOTA-tyr3-OCTREOTIDE
- Radiation
- Lead sponsor
- O'Dorisio, M S
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Pituitary Adenomas, Prolactinomas
- Interventions
- Lapatinib
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts